Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H20N2O4S |
| Molecular Weight | 372.438 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
InChI
InChIKey=OXVFDZYQLGRLCD-UHFFFAOYSA-N
InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)
| Molecular Formula | C19H20N2O4S |
| Molecular Weight | 372.438 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8978836
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8978836
Hydroxypioglitazone (M-IV) is an active metabolite of the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. Experiments in vitro have shown that hydroxypioglitazone was more efficient than the parent drug in stimulating lipid synthesis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study. | 2014-10-15 |
|
| Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study. | 2013-07-01 |
|
| Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. | 1996-12-20 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:33:08 GMT 2025
by
admin
on
Mon Mar 31 18:33:08 GMT 2025
|
| Record UNII |
K824X25AYA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
552716
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
||
|
FDA ORPHAN DRUG |
700919
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EU/3/16/1770(POSITIVE)
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | Treatment of adrenoleukodystrophy 18/11/2016 Positive | ||
|
146062-44-4
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
SUB196367
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
4147757
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
10868
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
C170108
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
DTXSID30399914
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
GH-65
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
100000182339
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
DB15021
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY | |||
|
K824X25AYA
Created by
admin on Mon Mar 31 18:33:08 GMT 2025 , Edited by admin on Mon Mar 31 18:33:08 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |